Search
Antigen peptide transporter 1
go.drugbank.com/bio_entities/BE0003109TransporterHumansIn complex with TAP2 mediates unidirectional translocation of peptide antigens from cytosol to endoplasmic reticulum (ER) for loading onto MHC class I (MHCI) molecules (PubMed:25377891, PubMed:25656091
Synonyms: Peptide transporter involved in antigen processing 1Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalan important role in tumor cell growth and survival. … of cell growth in tumors that overexpress Trk.
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational, and improvements in CF symptoms. … results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes.
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalThe ophthalmic solution was approved in July, 2016 under the trade name Xiidra. … It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Categories: Compounds used in a research, industrial, or household settingPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigational[A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast
Vepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies … [A275507, A275509] In a global, randomized Phase III clinical trial (VERITAC-2), vepdegestrant was clinically evaluated and compared against the injectable selective estrogen receptor degrader (SERD) [
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalbreast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitorsSimoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedSimoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line. … Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life [A31525]
Soybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalIt is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use. … It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat.
Mixtures: Liposyn II Inj 10%, Liposyn IIProducts: LIPOFUNDIN 20 %N, LIPOFUNDIN 10 %N